fresh video/podcast @11am
Reminder today @ 4 o clock !!!!
Date & TimeFeb 6, 2025 16:00 in
DescriptionLiquid biopsy analytes including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) represent important minimally invasive biomarker sources for molecular profiling as a step towards realizing precision oncology.
In this webinar, Anne-Sophie Pailhes-Jimenez will present dual analysis data from samples taken from lung cancer patients using Parsortix system by ANGLE. Targeted next-generation sequencing (NGS) on the NextSeq 2000 sequencer was performed and revealed mutations identified exclusively on CTCs compared to cfDNA. Overall, dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care |
Nice, clear video AN interview on the Angle website, explaining today's novel findings using the Parsortix system demonstrating the role of CTC:B cell clusters in driving cancer progression - complete with closing cheesy grin...... |
Already registerered… I hope Anne-Sophie is well drilled and the presentation slick…
The regulatory RNSs are sometimes frustrating but the way the indications are expanding with this fundamental research completed by leaders in their fields illustrates the potential multiple indications in the research space, some of which will translate to the prognostic/predictive markers which will really drive mass adoption. Research adoption is a lot about networking and achieving critical mass by persuading others to jump on the bandwagon… With the best solution.
And with that regulatory RNS there was a classic suck in the sellers… So we’ve got some stock for the buyers later… |
I truly hope and pray that the developments in the past few weeks come to fruition through long and medium term revenue contracts. If , as previously, this all turns to dust then sadly I really fear we are drinking in the last chance saloon |
today !!!!
Date & TimeFeb 6, 2025 16:00 in
DescriptionLiquid biopsy analytes including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) represent important minimally invasive biomarker sources for molecular profiling as a step towards realizing precision oncology.
In this webinar, Anne-Sophie Pailhes-Jimenez will present dual analysis data from samples taken from lung cancer patients using Parsortix system by ANGLE. Targeted next-generation sequencing (NGS) on the NextSeq 2000 sequencer was performed and revealed mutations identified exclusively on CTCs compared to cfDNA. Overall, dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care |
Hence he’s an ambulance assistant . |
Purchaseatthetop currently trolling Here .....VAST and MOS....and yet he lost over 200k last year in ENET so his financial advice is useless. Strange how all the ones he's trolling are doing well....... |
It's about building momentum and interest in a start up like Angle. That's how it works. |
True. It’s about £170 or so. Interesting info but just another one in a long line that have not turned into revenue. |
PATT - absolutely no relevance to anything I wrote.
barnes - RNS are not expensive. |
It’s not about understanding the area it is about spending money on unnecessary rns releases that they can barely afford
It is common sense and it won’t be long before the market catches on to this nonsense |
Ok Barnes - you're obviously well researched and understand this area better than experts in the field. |
Nigel it is fluff and a waste of money to be honest |
This is from a third party.
I don't think you can rationally describe this as "non-RNS" or "fluff" to be honest.
"The unique features of the Parsortix system have enabled my team to undertake pioneering research in this promising field. We consider the Parsortix system to be the best and most suitable technology to capture and interrogate homotypic and heterotypic CTC clusters, from patient blood samples and preclinical models of cancer, and the most advanced technology capable of harvesting large numbers of CTC clusters. We are excited to build on this discovery and its importance for developing treatment strategies which can predict, and/or prevent metastatic disease." |
ANGLE’s Parsortix system helps uncover key cancer spread mechanism |
High time this outfit put some proper contract news out instead of all this fluff
Which everyone can see right through |
The gift that keeps on giving!
Add digoxin as an immediate step to slow of inhibit progression whilst you do further testing on the sample to check the protein signals |
Mind boggling research from Prof. Marchetti and worth reading his bio:-
'recognized expert and international Authority in the biology and clinical utilities of Circulating Tumor Cells (CTCs) '
This is completely independent research and the fact that a leading expert in the field has chosen to use the Parsortix system is very encouraging. |
Another non RNS. There have been so many of these. We all know that researchers love Parsortix. The issue is why it has not been commercialised by now. A proper revenue RNS is needed. |
What a shame that Advfn does not flag these non-rns's up on my monitor, this one had completely passed me by, so thanks to patsym and sawney for alerting me to its existence.
With this and the webinar later on we are in for an interesting day. |
To reiterate....
Professor Dario Marchetti, The University of New Mexico Comprehensive Cancer Center, commented....
"The unique features of the Parsortix system have enabled my team to undertake pioneering research in this promising field. We consider the Parsortix system to be the best and most suitable technology to capture and interrogate homotypic and heterotypic CTC clusters, from patient blood samples and preclinical models of cancer, and the most advanced technology capable of harvesting large numbers of CTC clusters". |
 ANGLE plc ("the Company") NOVEL FINDINGS USING THE PARSORTIX SYSTEM DEMONSTRATE ROLE OF CTC:B CELL CLUSTERS IN DRIVING CANCER PROGRESSION Findings may enable the development of novel drugs to target B cell and CTC cluster interactions to suppress cancer metastasis This pivotal work is likely to stimulate further interest in the Parsortix system to investigate metastasis and drive clinical trials ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce the publication of novel research by Professor Dario Marchetti's team at the University of New Mexico Comprehensive Cancer Center, United States. The study used the Parsortix® system to investigate CTC and B cell* clusters in clinical and pre-clinical models of melanoma brain metastasis, and their ability to target additional organs during the spread of cancer ("metastasis of metastasis"). This pivotal work is likely to stimulate further interest in using the Parsortix system to investigate the process of metastasis and drive clinical trials to develop new drugs to suppress metastasis, powered by the Parsortix system. By employing a newly developed humanised mouse model, the Marchetti team demonstrated that the aggregation of B cells with CTCs, in CTC clusters, enables cancer cells to be masked from the immune system enhancing their metastatic potential. This finding increases our understanding of cancer progression and may allow for the development of new treatments to suppress cancer metastasis. Notably, in an additional experiment, the researchers found a significantly higher number of CTC:B cell clusters in blood samples from early stage clinical melanoma patients that later progressed to develop metastatic disease, compared to patients with existing metastasis. They hypothesised that these CTC:B cell clusters may enhance the metastatic process and amplify treatment resistance to immunotherapies. This could be of profound clinical importance in determining which patients have aggressive disease and in assessing their likely response to immunotherapy. A second major finding of the study was to show that a specific gene signature within CTC clusters acts like a postcode to guide CTCs from the brain to the liver, thereby forming secondary liver metastasis which is associated with poor patient outcomes. The discovery of a melanoma brain-liver axis, and by implication similar axes for other sites in the body, could have important clinical consequences for treating metastatic melanoma and identifying novel drug targets for treatment. The Parsortix system played an instrumental role in this research, demonstrating another pivotal discovery made possible by ANGLE's unique, marker-independent system which enables the collection of live CTC clusters for downstream analysis. Professor Dario Marchetti, The University of New Mexico Comprehensive Cancer Center, commented:"We are delighted to publish these novel findings which provide further insight into the metastatic cascade as culmination of tumour progression. The clinical potential of understanding how and why CTC clusters co-opt B cells to cause fatal metastasis is of unique relevance to patient care and may lead to new treatment options. The study of CTC clustering with immune cells has allowed the discovery of a 'postcode' that tells us which organ the metastasis will target next. This is the first evidence that the direction of metastasis from primary to secondary disease has been reported and could enable the development of a novel class of compounds to target the metastatic spread of cancer. The unique features of the Parsortix system have enabled my team to undertake pioneering research in this promising field. We consider the Parsortix system to be the best and most suitable technology to capture and interrogate homotypic and heterotypic CTC clusters, from patient blood samples and preclinical models of cancer, and the most advanced technology capable of harvesting large numbers of CTC clusters. We are excited to build on this discovery and its importance for developing treatment strategies which can predict, and/or prevent metastatic disease." Chief Scientific Officer, Karen Miller, commented:"We are delighted to see another CTC cluster-based discovery shedding light on the metastatic cascade that was fundamentally made possible by the Parsortix system. We share Professor Marchetti's excitement for this innovative and impactful work and congratulate his team on these novel findings. Furthermore, we are extremely proud to see the Parsortix system playing an instrumental part in such pioneering discoveries in cancer research and the implications for drug discovery. We anticipate that interest in the Parsortix system will increase as commercial and academic research into the metastatic pathway continues to build." |
gooosed,
Thanks for that, we've seen several papers and articles from researchers outlining the need to look at both ctDNA and CTCs in order to get a more comprehensive picture and Angle's timely research on combined ctDNA and CTC analysis simply reinforces this.
So far Angle have shown that CTCs from the majority (sometimes all) of lung, breast, prostate and ovarian cancer patients had druggable mutations that were not present in ctDNA from the same blood sample. It would surely be very dangerous for the NHS to rely on ctDNA analysis alone as a substitute for tissue biopsy. It's one thing using ctDNA liquid biopsy as a screening tool for early detection but quite another to make ife or death treatment decisions for patients with existing disease.
There is clearly a role to play for CTC liquid biopsy and let's hope Angle are able to take advantage of it. The institutions mentioned in your link are certainly aware of and have been using Parsortix in their research. |
Which is why I was saying how would revenues rise to cover the annual overhead. It is perfectly OK to compare to the challenges that other shares have faced. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
